(Q43750850)

26 November 2017

title

Anti-human immunodeficiency virus type 1 humoral immune response and highly active antiretroviral treatment (English)

1 reference

26 November 2017

main subject

anti-retroviral agent

0 references

4

Beatriz Grinsztejn

1 reference

26 November 2017

5

Valdilea Veloso

1 reference

26 November 2017

Mariza Gonçalves Morgado

8

object named as

Mariza G Morgado

1 reference

26 November 2017

Jose Henrique Pilotto

7

object named as

José H Pilotto

1 reference

26 November 2017

1

Vera Bongertz

1 reference

26 November 2017

E Priscilla Ouverney

2

1 reference

26 November 2017

Saada Chequer Fernandez

3

1 reference

26 November 2017

José C Couto-Fernandez

6

1 reference

26 November 2017

language of work or name

1 reference

1 November 2007

1 reference

Memórias do Instituto Oswaldo Cruz

26 November 2017

published in

1 reference

26 November 2017

volume

102

1 reference

26 November 2017

issue

7

1 reference

26 November 2017

page(s)

817-825

1 reference

Seroreversion of HIV antibodies in patients with prolonged suppression of viraemia under HAART.

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Isotype profiles of anti-gp160 antibodies from HIV-infected patients in plasma and culture supernatants

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Immunological and virological effects of structured treatment interruptions following exposure to hydroxyurea plus didanosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

HIV-1 diversity in Brazil: genetic, biologic, and immunologic characterization of HIV-1 strains in three potential HIV vaccine evaluation sites. Brazilian Network for HIV Isolation and Characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Vertical HIV-1 transmission: importance of neutralizing antibody titer and specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Human immunodeficiency virus type 1 neutralization by plasma from B or F genotype infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

CD4+ T-cell recovery and clinical outcome in HIV-1-infected patients exposed to multiple antiretroviral regimens: partial control of viremia is associated with favorable outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Perspectives on inducing efficient immune control of HIV-1 replication--a new goal for HIV therapeutics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Serotyping HIV-1 with V3 peptides: detection of high avidity antibodies presenting clade-specific reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Absence of seroreversion in 80 HAART-treated HIV-1 seropositive patients with at least five-years undetectable plasma HIV-1 viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Molecular epidemiology of HIV-1 infection in a small Brazilian county: usefulness of envelope and polymerase sequences to epidemiologic studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

High frequency of recombinant genomes in HIV type 1 samples from Brazilian southeastern and southern regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

The effects of early antiretroviral therapy and its discontinuation on the HIV-specific antibody response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Reconstitution of spontaneous neutralizing antibody response against autologous human immunodeficiency virus during highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Systematic determination of the packaging limit of lentiviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Optimal timing and best antiretroviral regimen in treatment-naive HIV-infected individuals with advanced disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Characterization of the HIV-1 specific humoral immune response during highly active antiretroviral therapy (HAART).

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Restoration of human immunodeficiency virus-1-specific responses in patients changing from protease to non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Emergence of autologous neutralization-resistant variants from preexisting human immunodeficiency virus (HIV) quasi species during virus rebound in HIV type 1-infected patients undergoing highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Low CD4+T Cell Nadir Is an Independent Predictor of Lower HIV‐Specific Immune Responses in Chronically HIV‐1–Infected Subjects Receiving Highly Active Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Millions of Life‐Years Saved with Potent Antiretroviral Drugs in the United States: A Celebration, with Challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Immune Reconstitution after Receipt of Highly Active Antiretroviral Therapy in Children with Advanced or Progressive HIV Disease and Complete or Partial Viral Load Responsea

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

Primary HIV-1 drug resistance in Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0074-02762007005000119

10.1590/S0074-02762007005000119

21 January 2018

Identifiers

DOI

1 reference

26 November 2017

1 reference